Effective combination therapy of bortezomib and dexamethasone for a plasma cell leukemia patient with multiple osteolytic lesions and extramedullary involvement [4]

Acta Oncologica

Volumn 46, Issue 2, 2007, Pages 262-264

  Capalbo, Silvana ^a   Chiefa, Antonia ^a   Delia, Mario ^a   Diomede, Daniela ^a   Liso, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; BLOOD TOXICITY; BONE ATROPHY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER THERAPY; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; PERIPHERAL NEUROPATHY; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; WEAKNESS; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; LEUKEMIA, PLASMACYTIC; MIDDLE AGED; PYRAZINES; SKULL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33847024022     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860600897975     Document Type: Letter

References (8)

1. San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A pratical update on the use of bortezomib in the management of multiple myeloma. The Oncologist 2006;11:51-61.
2. Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005;114:665-7.
3. Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005;25:1820-5.
4. Grassinger J, Sudhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006;85:132-3.
5. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response in patients with multiple myeloma treated with high-dose therapy and hemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
6. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C, et al. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005;78:288-94.
7. Jimenez-Zepeda VH, Dominguez VJ. Plasma cell leukemia: A rare condition. Ann Hematol 2006;85:263-7.
8. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-3.